Updated: January 18, 2026

Qsymia Shortage Update: What Patients Need to Know in 2026

Author

Peter Daggett

Summarize with AI

Is Qsymia in an Official Shortage in 2026?
Why Does Qsymia Feel Like It's in Short Supply?
Has Qsymia Ever Been in a Formal Shortage?
Key 2026 Updates for Patients
What Should I Do If I Can't Find Qsymia?

Qsymia isn't in an FDA-declared shortage, but REMS restrictions and insurance barriers make it hard for many patients to access. Here's the latest update for 2026.

If you've tried to fill a Qsymia prescription recently and had trouble, you might be wondering whether the medication is in shortage. The answer is nuanced: Qsymia (phentermine/topiramate extended-release) is not on the FDA's official drug shortage list as of 2026. But that doesn't mean it's easy to find. A combination of distribution restrictions, insurance barriers, and high demand for weight-loss medications means that many patients still struggle to fill their prescriptions.

Is Qsymia in an Official Shortage in 2026?

No. As of 2026, Qsymia is not listed on the FDA Drug Shortages database. Vivus (the manufacturer) has not reported any production or supply problems. The medication is being manufactured and is available in the U.S. market.

However, patients experience something that feels like a shortage for a different reason: the FDA requires that Qsymia only be dispensed at pharmacies certified under the Qsymia REMS program. This limited distribution network is what creates access problems—not a lack of manufactured product.

Why Does Qsymia Feel Like It's in Short Supply?

Several factors converge to create access difficulties for patients:

REMS-restricted distribution. Most retail pharmacies are not certified to dispense Qsymia. Because topiramate (one of Qsymia's active ingredients) carries serious birth defect risks, the FDA requires a formal safety program that limits dispensing to certified pharmacies only.

Surging demand for weight-loss medications. The obesity treatment landscape has grown dramatically. GLP-1 receptor agonists like Wegovy and Zepbound have sparked wider awareness about weight management, leading more patients to seek all types of obesity medications—including Qsymia.

Insurance coverage gaps. Many insurance plans—including most Medicare Part D plans—do not cover weight-loss medications. Prior authorization requirements further delay access even when coverage exists.

DEA quota limitations. Because phentermine is a Schedule IV controlled substance, annual production is subject to DEA quota limits. While this is not currently causing a formal shortage, rapid increases in prescribing volume can create regional allocation pressures.

Has Qsymia Ever Been in a Formal Shortage?

Qsymia has not historically been listed on the FDA's drug shortage database. The ongoing access challenges patients experience are structural—related to REMS distribution—rather than a supply-chain breakdown like the ones seen with GLP-1 medications in 2023–2024. Vivus has worked to expand access by allowing home delivery through Qsymia Engage and by partnering with GoodRx to make Qsymia available at $149/month at 70,000+ retail pharmacies.

Key 2026 Updates for Patients

Generic now available. The first generic version of phentermine/topiramate extended-release was approved and released in May 2025. Generic versions are subject to the same REMS restrictions but may be available at more pharmacies and at lower prices. Ask your pharmacist or provider if the generic is an option.

FDA removed strict BMI requirements. The FDA recently removed specific BMI thresholds from Qsymia's prescribing criteria, giving providers more flexibility in determining which patients are appropriate candidates. This may expand the pool of patients who can be prescribed Qsymia.

Improved cardiovascular data. A postmarketing study showed that Qsymia does not raise blood pressure in the way standalone phentermine does—actually demonstrating a reduction in 24-hour mean systolic blood pressure. This removes a longstanding concern and may make Qsymia more accessible to patients with cardiovascular risk factors.

Home delivery savings. The Qsymia Engage home delivery program offers $89/month (30-day) or $70/month for a 90-day supply, making it one of the most cost-effective access pathways outside of using a discount card at a certified retail pharmacy.

What Should I Do If I Can't Find Qsymia?

Search with medfinder. medfinder.com calls certified pharmacies near you to find which ones can fill your specific Qsymia dose.

Try home delivery. Visit QsymiaEngage.com to set up home delivery through LifeLine Specialty Pharmacy for $89/month.

Ask about the generic. The generic version released in May 2025 may be available at a wider range of certified pharmacies and at lower cost.

Use discount programs. GoodRx ($149/month), SingleCare (as low as ~$63/month), and the manufacturer's savings card ($75 off per fill for cash-pay patients) can significantly lower costs.

If none of these work, discuss alternative medications with your provider. Contrave, Wegovy, Zepbound, or separate phentermine + topiramate generics may be viable options.

For step-by-step guidance on locating Qsymia, see our detailed guide: How to Find Qsymia in Stock Near You.

Frequently Asked Questions

Qsymia is not on the FDA's official drug shortage list in 2026. The access difficulties patients experience are caused by the FDA-required REMS distribution program, which limits dispensing to certified pharmacies only—not by a manufacturing or supply chain shortage.

Most pharmacies are not certified under the Qsymia REMS program and cannot legally fill Qsymia prescriptions. Combined with insurance coverage gaps, prior authorization requirements, and rising demand for weight-loss medications, this creates significant access barriers that feel like a shortage even though no formal shortage exists.

No. Qsymia has not been recalled or withdrawn from the market. It has been available since its initial FDA approval in July 2012 for adults and has remained on the market continuously. It received expanded approval for pediatric patients 12 and older in 2022.

Yes. The first generic version of phentermine/topiramate extended-release was released in May 2025. Generics are subject to the same REMS distribution restrictions as brand-name Qsymia but may be available at additional certified pharmacies and at lower cost.

Yes. The FDA maintains an active drug shortage database at accessdata.fda.gov/scripts/drugshortages. You can search by drug name to see if Qsymia or any of its components are listed. As of 2026, Qsymia does not appear on this list.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards